Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus
U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
GSK plc: GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
WPTV4d
FDA approves first new antibiotic treatment for UTIs in decades
A new antibiotic has been approved to treat urinary tract infections by the Food and Drug Administration for the first time ...
ViiV Healthcare's APRETUDE Now Covered Under Canada's NIHB Program For HIV Prevention
ViiV Healthcare, a global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, Wednesday announced that APRETUDE ...
FDA approves new antibiotic to treat UTIs in females
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
Le Lézard4d
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir ...
BioSpace4d
GSK Wins FDA Nod for First Oral UTI Antibiotic in Almost 30 Years
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...
US FDA approves GSK's 'Blujepa' for treating UTIs in women and girls
The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the ...